Literature DB >> 33300546

Pre-pouch Ileitis is Associated with Development of Crohn's Disease-like Complications and Pouch Failure.

Gaurav Syal1,2, Ron Shemtov3, Nirupama Bonthala1,2, Eric A Vasiliauskas1,2, Edward J Feldman1,2, Karen Zaghiyan4, Christina Y Ha1,2, Dermot P B McGovern1,2, Stephan R Targan1,2, Gil Y Melmed1,2, Phillip R Fleshner1,4.   

Abstract

BACKGROUND AND AIMS: It is unclear whether pre-pouch ileitis heralds an aggressive inflammatory pouch disease in patients with ileal pouch-anal anastomosis [IPAA]. We compared outcomes of patients with pouchitis and concomitant pre-pouch ileitis with those with pouchitis alone.
METHODS: Patients undergoing IPAA surgery for inflammatory bowel disease, who subsequently developed pouchitis with concomitant pre-pouch ileitis [pre-pouch ileitis group], were matched by year of IPAA surgery and preoperative diagnosis [ulcerative colitis or inflammatory bowel disease-unclassified] with patients who developed pouchitis alone [pouchitis group]. Primary outcomes were development of Crohn's disease [CD]-like complications [non-anastomotic strictures or perianal disease >6 months after ileostomy closure] and pouch failure. Secondary outcomes were need for surgical/endoscopic interventions and immunosuppressive therapy. Log-rank testing was used to compare outcome-free survival, and Cox regression was performed to identify predictors of outcomes.
RESULTS: There were 66 patients in each group. CD-like complications and pouch failure developed in 36.4% and 7.6% patients in the pre-pouch ileitis group and 10.6% and 1.5% in pouchitis group, respectively. CD-like complications-free survival [log-rank p = 0.0002] and pouch failure-free survival [log-rank p = 0.046] were significantly lower in the pre-pouch ileitis group. The pre-pouch ileitis group had a higher risk of requiring surgical/endoscopic interventions [log-rank p = 0.0005] and immunosuppressive therapy [log-rank p <0.0001]. Pre-pouch ileitis was independently associated with an increased risk of CD-like complications (hazard ratio [HR] 3.8; p = 0.0007), need for surgical/endoscopic interventions [HR 4.1; p = 0.002], and immunosuppressive therapy [HR 5.0; p = 0.0002].
CONCLUSIONS: Pre-pouch ileitis is associated with a higher risk of complicated disease and pouch failure than pouchitis. It should be considered a feature of CD.
© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; Pre-pouch ileitis; afferent limb inflammation

Mesh:

Substances:

Year:  2021        PMID: 33300546      PMCID: PMC8218713          DOI: 10.1093/ecco-jcc/jjaa251

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  23 in total

1.  A Comprehensive Approach to Pouch Disorders.

Authors:  Kevin P Quinn; Amy L Lightner; William A Faubion; Laura E Raffals
Journal:  Inflamm Bowel Dis       Date:  2019-02-21       Impact factor: 5.325

2.  Elevated serum IgG4 is associated with chronic antibiotic-refractory pouchitis.

Authors:  Udayakumar Navaneethan; Preethi G K Venkatesh; Sumit Kapoor; Ravi P Kiran; Feza H Remzi; Bo Shen
Journal:  J Gastrointest Surg       Date:  2011-07-03       Impact factor: 3.452

Review 3.  Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis.

Authors:  L Peyrin-Biroulet; A Germain; A S Patel; J O Lindsay
Journal:  Aliment Pharmacol Ther       Date:  2016-08-17       Impact factor: 8.171

4.  Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort.

Authors:  Martin Gregory; Kimberly N Weaver; Patrick Hoversten; Stephen Bradley Hicks; Devin Patel; Matthew A Ciorba; Alexandra M Gutierrez; Poonam Beniwal-Patel; Sowmya Palam; Gaurav Syal; Hans H Herfarth; George Christophi; Laura Raffals; Edward L Barnes; Parakkal Deepak
Journal:  Inflamm Bowel Dis       Date:  2019-08-20       Impact factor: 5.325

5.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

6.  Afferent limb ulcers predict Crohn's disease in patients with ileal pouch-anal anastomosis.

Authors:  Jason M Wolf; Jean-Paul Achkar; Bret A Lashner; Conor P Delaney; Robert E Petras; John R Goldblum; Jason T Connor; Feza H Remzi; Victor W Fazio
Journal:  Gastroenterology       Date:  2004-06       Impact factor: 22.682

7.  Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States.

Authors:  Fang Xu; Yong Liu; Anne G Wheaton; Kristina M Rabarison; Janet B Croft
Journal:  Appl Health Econ Health Policy       Date:  2019-02       Impact factor: 2.561

8.  Inflammatory Pouch Conditions Are Common After Ileal Pouch Anal Anastomosis in Ulcerative Colitis Patients.

Authors:  Maia Kayal; Michael Plietz; Anam Rizvi; Marlana Radcliffe; Alexa Riggs; Clara Yzet; Emily Tixier; Parth Trivedi; Ryan C Ungaro; Sergey Khaitov; Patricia Sylla; Alexander Greenstein; Jean Frederic Colombel; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2020-06-18       Impact factor: 5.325

9.  Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort.

Authors:  Kimberly N Weaver; Martin Gregory; Gaurav Syal; Patrick Hoversten; Stephen Bradley Hicks; Devin Patel; George Christophi; Poonam Beniwal-Patel; Kim L Isaacs; Laura Raffals; Parakkal Deepak; Hans H Herfarth; Edward L Barnes
Journal:  Inflamm Bowel Dis       Date:  2019-03-14       Impact factor: 5.325

10.  Prepouch Ileitis After Ileal Pouch-anal Anastomosis: Patterns of Presentation and Risk Factors for Failure of Treatment.

Authors:  Matteo Rottoli; Carlo Vallicelli; Eleonora Bigonzi; Paolo Gionchetti; Fernando Rizzello; Massimo P Di Simone; Gilberto Poggioli
Journal:  J Crohns Colitis       Date:  2018-02-28       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.